Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
CADTH
Record ID 32012000656
English
Authors' recommendations:
At present, there is insufficient evidence to determine the clinical benefit and harm of adding boceprevir or telaprevir to PR in patients with CHC co-infected with HIV. CHC patients who are null responders to previous PR therapy may benefit from telaprevir-PR, although the response rate is expected to be lower than in the general CHC population. There are no RCT data on this population for boceprevir-PR. Similar to the overall trial populations in the included studies, patients with CHC infection and metavir scores of F0 or F1 (telaprevir) or F0-F2 (boceprevir) achieved higher SVR rates with protease inhibitors added to PR over PR alone. Response rates with PI-PR were generally higher at earlier stages of fibrosis compared with later stages in treatment-naïve patients, but not in treatment-experienced patients.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/mar-2012/RC0327-004%20Special%20Populations%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Protease Inhibitors
- Hepatitis C, Chronic
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.